PROTAC HK2 Degrader-1

• UNSPSC Description:

  PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research[1].

• Target Antigen:

  Hexokinase; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-hk2-degrader-1.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(N1)CCC(N(C(C2=C3C=CC=C2NCCCCNC(C4=NN(C5=C4C=CC=C5)CC6=C(C=C(C=C6)Cl)Cl)=O)=O)C3=O)C1=O

• Molecular Weight:

  647.51

• References & Citations:

  [1]Sang R, et al. Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy. J Med Chem. 2023 Jun 27.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3033812-84-6